HER2 status determination using RNA-ISH - a rapid and simple technique showing high correlation with FISH and IHC in 141 cases of breast cancer

Histology and Histopathology

Volumn 27, Issue 8, 2012, Pages 1021-1027

  Alba, Javier ^a   Gutierrez, Javier ^b   Coupe, Victoria Mary ^b   Fernández, Beatriz ^a   Vázquez Boquete, Ángel ^a   Alba, Jesús ^b   Forteza, Jerónimo ^a   García Caballero, Tomás ^a  

^a Instituto de Salud Carlos III   (Spain)

^b CENBIMO   (Spain)

Author keywords

Breast cancer; ErbB2; FISH; HER2; IHC; RNA ISH

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MESSENGER RNA; RNA;

ARTICLE; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LUNG CARCINOMA; METABOLISM; METHODOLOGY; NUCLEIC ACID HYBRIDIZATION; REPRODUCIBILITY;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; NUCLEIC ACID HYBRIDIZATION; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; RNA, NEOPLASM;

EID: 84864956021     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Azim H., Azim H.A. Jr and Escudier B. (2009). Trastuzumab versus lapatinib: the cardiac side of the story. Cancer Treat. Rev. 35, 633-638.
2. Baselga J. and Swain S.M. (2009). Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9, 463-475.
3. Bhargava R., Lal P. and Chen B. (2005). Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and lowlevel amplification: does it measure up to fluorescence in situ hybridization? Am. J. Clin. Pathol. 123, 237-243
4. Bilous M., Dowsett M., Hanna W., Isola J., Lebeau A., Moreno A., Penault-Llorca F., Rüschoff J., Tomasic G. and van de VIjver M. (2003). Current perspectives on HER2 testing: a review of national testing guidelines. Mod. Pathol. 16, 173-182.
5. Child S.J., Miller M.K. and Geballe A.P. (1999). Cell type-dependent and-independent control of HER-2/neu translation. Int. J. Biochem. Cell. Biol. 31, 201-213.
6. Garcia-Caballero T., Grabau D., Green A.R., Gregory J., Schad A., Kohlwes E., Ellis I.O., Watts S. and Mollerup J. (2010). Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology 56, 472-480.
7. Hawkins J.W. and Dugaiczyk A. (1982). The human serum albumin gene: structure of a unique locus. Gene 19, 55-58.
8. Hung M.C. and Lau Y.K. (1999). Basic science of HER-2/neu: a review. Semin. Oncol. 26, 51-59.
9. Hynes N.E. and MacDonald G. (2009). ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell. Biol. 21, 177-184.
10. Kedrin D., Wyckoff J., Boimel P.J., Coniglio S.J., Hynes N.E., Arteaga C.L. and Segall J.E. (2009). ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation. Clin. Cancer. Res. 15, 3733-3739.
11. Kraus M.H., Popescu N.C., Amsbaugh S.C. and King C.R. (1987). Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 6, 605-610.
12. Kurosumi M. (2009). Recent trends of HER-2 testing and trastuzumab therapy for breast cancer. Breast Cancer 16, 284-287.
13. Laudadio J., Quigley D.I., Tubbs R. and Wolff D.J. (2007). HER2 testing: a review of detection methodologies and their clinical performance. Expert. Rev. Mol. Diagn. 7, 53-64.
14. Menard S., Pupa S.M., Campiglio M. and Tagliabue E. (2003). Biologic and therapeutic role of HER2 in cancer. Oncogene 22, 6570-6578.
15. Rosa F.E., Silveira S.M., Silveira C.G., Bergamo N.A., Neto F.A., Domingues M.A., Soares F.A. Caldeira J.R. and Rogatto S.R. (2009). Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma. BMC Cancer 9, 90.
16. Ross J.S., Slodkowska E.A., Symmans W.F., Pusztai L., Ravdin P.M. and Hortobagyi G.N. (2009). The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14, 320-368.
17. Roy V. and Perez E.A. (2009). Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist 14, 1061-1069.
18. Sauter G., Lee J., Bartlett J.M., Slamon D.J. and Press M.F. (2009). Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J. Clin. Oncol. 27, 1323-1333.
19. Savino M., Parrella P., Copetti M., Barbano R., Murgo R., Fazio V.M., Valori V.M., Carella M., Garrubba M. and Santini S.A. (2009). Comparison between real-time quantitative PCR detection of HER2 mRNA copy number in peripheral blood and ELISA of serum HER2 protein for determining HER2 status in breast cancer patients. Cell. Oncol. 31, 203-211.
20. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A. and Press M.F. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712.
21. Walker R.A., Bartlett J.M., Dowsett M., Ellis I.O., Hanby A.M., Jasani B., MIller K. and Pinder S.E. (2008). HER2 testing in the UK: further update to recommendations. J. Clin. Pathol. 61, 818-82.
22. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Alfred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A, McShane L.M., Plk S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., van de Vijver M., Wheeler T.M. and Hayes D.F. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25, 118-145.
23. Wood W.G. (1996). The complexities of beta globin gene regulation. Trends. Genet. 12, 204-206.